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The present study evaluated the possible role of a-adrenergic receptors of the dorsal hippocampus on 
scopolamine-induced amnesia and scopolamine state-dependent memory in adult male Wistar rats. 
The animals were bilaterally implanted with chronic cannulae in the CA1 regions of the dorsal hippocam­
pus, trained in a step-through type inhibitory avoidance task, and tested 24 h after training to measure 
step-through latency. Results indicate that post-training or pre-test intra-CA1 administration of scopol­
amine (1 and 2 lg/rat) dose-dependently reduced the step-through latency, showing an amnestic 
response. Amnesia produced by post-training scopolamine (2 lg/rat) was reversed by pre-test adminis­
tration of the scopolamine that is due to a state-dependent effect. Interestingly, pre-test intra-CA1 micro-
injection of a1-adrenergic agonist, phenylephrine (1 and 2 lg/rat) or a2-adrenergic agonist, clonidine 
improved post-training scopolamine (2 lg/rat)-induced retrieval impairment. Furthermore, pre-test 
intra-CA1 microinjection of phenylephrine (0.25, 0.5 and 1 lg/rat) or clonidine (0.25, 0.5 and 1 lg/rat) 
with an ineffective dose of scopolamine (0.25 lg/rat), synergistically improved memory performance 
impaired by post-training scopolamine. On the other hand, pre-test injection of a1-receptors antagonist 
prazosin (1 and 2 lg/rat) or a2-receptors antagonist yohimbine (1 and 2 lg/rat) prevented the restora­
tion of memory by pre-test scopolamine. It is important to note that pre-test intra-CA1 administration 
of the same doses of prazosin or yohimbine, alone did not affect memory retrieval. These results suggest 
that a1- and a2-adrenergic receptors of the dorsal hippocampal CA1 regions may play an important role 
in scopolamine-induced amnesia and scopolamine state-dependent memory. 
© 2010 Elsevier Inc. All rights reserved. 1. Introduction 
The importance of cholinergic systems in learning and memory 
has been shown previously (Blokland, 1995). Evidence suggested 
that acetylcholinesterase inhibitors, which enhance the availability 
of acetylcholine in the synaptic cleft improve performance in several 
cognitive models in both rodents and humans, whereas anticholin­
ergic drugs impair learning and memory in a variety of tasks (Fibiger, 
Damsma, & Day, 1991; Gallagher & Colombo, 1995; Power, Vazdarja­
nova, & McGaugh, 2003; Zarrindast, Bakhsha, Rostami, & Shafaghi, 
2002). There is also evidence that learning functionally modiﬁes search Branch, Islamic Azad 
ran University of Medical 
2569. 
oo.ca (M.-R. Zarrindast). 
ll rights reserved. cholinergic neurons, which become progressively more active. For 
instance, release of Ach in the hippocampus increases during perfor­
mance of a learned spatial memory task (Stancampiano, Cocco, 
Cugusi, Sarais, & Fadda, 1999). The increase in Ach is positively cor­
related with performance improvement during learning (Fadda, 
Robinson, Fratta, Pertwee, & Riedel, 2006). Scopolamine, a musca­
rinic cholinergic receptor antagonist, impairs memory performance 
that has been proposed as an animal model of dementia (Collerton, 
1986; Jensen, Stephens, Sarter, & Petersen, 1987; Quartermain & 
Leo, 1988). Similarities in the memory deﬁcits between Alzheimer 
patients and scopolamine treated animals have been reported. Thus, 
it has been proposed that scopolamine, could serve as a useful phar­
macological tool to produce a partial model of the disorder (Bartus, 
2000). Furthermore, along with cholinergic atrophy, monoamines 
are reduced in Alzheimer’s disease and the possibility may exist that 
enhancement of monoaminergic functions may elicit beneﬁcial 
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1989). 
The various areas of the brain, including the neocortex and the 
hippocampus are innervated by the ascending noradrenergic sys­
tem that originates in the locus coeruleus. Noradrenaline acts 
through two classes of receptors (a and b), both coupled with G-
proteins (Sirvio & MacDonald, 1999). a-adrenergic receptors are 
divided into two subtypes, differing in ligand speciﬁcity, kinetics, 
and effects. These receptors are expressed widely in the central 
nervous system (Berridge & Waterhouse, 2003; Sirvio & MacDon­
ald, 1999). a1-adrenoceptors were found to be mainly post-synap­
tic, whilst a2-adrenoceptors are localized both pre-synaptically 
and post-synaptically (Stuchlik, Petrasek, & Vales, 2008). Adrener­
gic receptors are involved in learning and memory. For example, 
noradrenaline enhances memory formation when administered 
into various brain regions including the hippocampus and entorh­
inal cortex (Izquierdo et al., 2000); and amygdale (Clayton & Wil­
liams, 2000; Hatﬁeld & McGaugh, 1999). Brain noradrenaline 
concentrations after training have been correlated with retention 
performance (Gold & van Buskirk, 1978).The mechanisms underly­
ing the function of this neurotransmitter in memory processing are 
unknown. However, the ability of noradrenaline to modulate the 
efﬁcacy of glutamate synaptic transmission via activation of G-pro­
tein-coupled adrenergic receptors seems likely (Scheiderer, Dob­
runz, & McMahon, 2004). 
Based on these ﬁndings the aim of the present study was to 
investigate the effects of bilateral microinjections of a1- or a2­
adrenergic receptor agents into the CA1 region of the dorsal hippo-
campus on scopolamine-induced amnesia and scopolamine state-
dependent memory, by using an inhibitory avoidance task has 
been investigated. 2. Materials and methods 
2.1. Animals 
Adult male Wistar rats (Pasteur institute, Tehran, Iran) weighing 
220–270 g at time of surgery were used. They had free access to food 
and water, were housed four in a cage, and kept at (22 ± 2) °C under a 
12/12 h light–dark cycle (light beginning at 7:00 a.m.). All experi­
ments were carried out during the light phase between 8:00 and 
14:00. Experimental groups consisted of eight animals and each ani­
mal was tested once. All procedures were performed in accordance 
with institutional guidelines for animal care and use. 
2.2. Surgery 
Animals were anaesthetized intraperitoneally with a ketamine/ 
xylazine mixture (100 and 10 mg/kg, respectively) and placed in a 
stereotaxic frame (David Kopf Instruments, USA) with ﬂat-skull po­
sition. A midline incision was made and the skin and underlying 
periosteum retracted. Stereotaxic coordinates for the CA1 regions 
of dorsal hippocampi were AP: -3 mm from bregma, L: ±2 mm 
from midline and V: -2.8 mm from the skull surface (Paxinos & 
Watson, 2007). The cannulae were anchored to the skull with den­
tal cement, and then stainless steel stylets (27 gauge) were in­
serted into the guide cannulae to maintain patency prior to 
microinfusions. 
2.3. Drugs and microinfusions 
The drugs included scopolamine hydrobromide, yohimbine (To­
cris, UK) phenylephrine hydrochloride, prazosin hydrochloride and 
clonidine hydrochloride (Sigma, UK). All drugs were dissolved in 
sterile saline and were injected into CA1 of dorsal hippocampus. 2.4. Intra-CA1 injections 
For bilateral drug infusion, the animals were gently restrained 
by hand; the stylets were removed from the guide cannulae and re­
placed by 27-gauge injection needles (1 mm below the tip of the 
guide cannula). The injection solutions were administered in a to­
tal volume of 1 ll/rat (0.5 ll in each side) over a 60 s period. Injec­
tion needles were left in place for an additional 60 s to facilitate the 
diffusion of the drugs. 
2.5. Inhibitory avoidance apparatus 
A step-through inhibitory avoidance apparatus consisted of two 
compartments of the same size (20 x 20 x 30 cm3). In the middle 
of a dividing wall, a guillotine door (7.9 cm2) could be lifted man­
ually. The walls and ﬂoor of one compartment consisted of white 
opaque resin, the walls of the other compartment were dark. Stain­
less steel bars (3 mm in diameter and 1 cm intervals) constituted 
the ﬂoor of the dark compartment. Intermittent electric shocks 
(50 Hz, 3 s, 1 mA intensity) were delivered to the grid ﬂoor of the 
dark compartment by an isolated stimulator. 
2.6. Behavioral procedures 
Training was based on our previous studies (Zarrindast, Eidi, Eidi, 
& Oryan, 2002; Zarrindast, Farajzadeh, Rostami, Rezayof, & Nourjah, 
2005a). All animals were allowed to habituate in the experimental 
room (with light and sound attenuated) for at least 30 min prior to 
the experiments. Then, each animal was gently placed in the brightly 
lit compartment of the apparatus; after 5 s the guillotine door was 
opened and the animal was allowed to enter the dark compartment. 
The latency with which the animal crossed into the dark compart­
ment was recorded. Animals that waited more than 100 s to cross 
to the dark compartment were eliminated from the experiments. 
Once the animal crossed with all four paws to the next compartment, 
the guillotine door was closed and the rat was immediately with­
drawn from the compartment. The trial was repeated after 30 min 
as in the acquisition trial where after 5 s the guillotine door was 
opened and as soon as the animal crossed to the dark (shock) com­
partment the door was closed and a foot shock (50 Hz, 1 mA and 
3 s) was immediately delivered to the grid ﬂoor of the dark room. 
After 20 s, the rat was removed from the apparatus and placed tem­
porarily into its home cage. Two minutes later, the animal was re­
tested in the same way as in the previous trials; if the rat did not 
enter the dark compartment during 120 s a successful acquisition 
of IA response was recorded. Otherwise, when the rat entered the 
dark compartment (before 120 s) a second time, the door was closed 
and the animal received the shock again. After retesting, if the rat 
learned inhibitory avoidance response successfully, it was removed 
from the apparatus and received post-training injection of saline or 
scopolamine (intra-CA1) immediately. On the test day, intra-CA1 
infusions were performed 5 min prior to the test. For the study of 
memory 24 h after training, each animal was gently placed in the 
light compartment and after 5 s (sec) the door was opened, and 
Step-through latency (sec) was measured in absence of electric foot 
shocks, as indicators of inhibitory avoidance behavior. An upper cut­
off of 300 s was set. The retention test was also carried out between 
8:00 a.m. and 2:00 p.m. 
2.7. Data analysis 
The data are expressed as mean ± SEM. The statistical analysis 
was performed using one- and two-way analysis of variance (AN­
OVA). Post-hoc comparison of means was carried out with the Tu­
key test for multiple comparisons, when appropriate. The level of 
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Table 1 
Summary of experimental design. 
Figure Post-training treatment 
Intra-CA1 microinjection (lg/rat) 
Pre-test Treatment 
Intra-CA1 microinjection (lg/rat) 
Saline (1 ll/rat) Scopolamine Saline (1 ll/rat) Scopolamine Phenylephrine Prazosin Clonidine Yohimbine 
1 
2 
3 
4 
5 
6 
A 
B 
Left panel 
Middle panel 
Right panel 
Left panel 
Middle panel 
Right panel 
Left panel 
Right panel 
Left panel 
Middle panel 
Right Panel 
Left panel 
Right panel 
Schematic histology 
Actual histology 
1 
1 
1 
1 
1 
(0.5–2) 
2 
2 
2 
2 
2 
2 
2 
1 
1 
1 
1 
1 
1 
1 
(0.5–2) 
(0.25–2) 
0.25 
2 
0.25 
2 
(0–1) 
(0–1) 
(0–1) 
(0.5–2) 
(0.5–2) 
(0–1) 
(0–1) 
(0–1) 
(0.5–2) 
(0.5–2) 
Fig. 1. Location of the injection cannulae tips in the CA1 regions of the dorsal 
hippocampus of rat is shown in Fig. 1A. Veriﬁed section was taken from the atlas of 
Paxinos and Watson (2007) also is shown in Fig. 1B. statistical signiﬁcance was set at P < 0.05. Calculations were per­
formed using the SPSS statistical package. 
2.8. Histology 
After the testing sessions each rat was deeply anesthetized and 
1 ml of a 4% methylene-blue solution was bilaterally infused into 
the CA1 (0.5 ml/side), as described in the drug section, then decap­
itated and its brain removed and placed in formaldehyde (10%). 
After several days, the brains were sliced and the sites of injections 
were veriﬁed according to Paxinos & Watson, 2007. Only data from 
animals with correct cannulae implants (432 animals; 93.5% of the 
total) were included in the statistical analyses. 
2.9. Experimental design 
Eight animals were used in each experimental group. In exper­
iments where animals received one or two injections, the control 
groups also received one or two saline injections. The intervals of 
drug administration were based on previous studies in order to ob­
tain a maximum response. The experimental design has been sum­
marized in Table 1. 
2.9.1. Experiment 1: effect of scopolamine on memory retrieval 
In this experiment, the effect of post-training and pre-test 
administration of scopolamine on inhibitory avoidance response 
was examined. Four groups of animals received saline or different 
doses of scopolamine (0.5, 1 and 2 lg/rat, intra-CA1), immediately 
after training. On the test day, the animals received saline (1 ll/rat, 
intra-CA1) 5 min before the test. The other seven groups of animals 
received saline (1 ll/rat, intra-CA1) or scopolamine (2 lg/rat, in­
tra-CA1), immediately after training and pre-test (5 min before 
the test) injections of different doses of scopolamine (0.5, 1 and 
2 lg/rat, intra-CA1) (Fig. 2). 
2.9.2. Experiment 2: effects of pre-test administration of phenylephrine 
on memory retrieval in the presence or absence of scopolamine 
In this experiment, ﬁve groups of animals received saline (1 ll/ 
rat, intra-CA1) immediately after training and different doses of 
phenylephrine (0.0, 0.125, 0.25, 0.5 and 1 lg/rat, intra-CA1) plus 
saline (1 ll/rat, intra-CA1) 5 min prior to testing. Another ﬁve 
groups received post-training administration of scopolamine 
(2 lg/rat, intra-CA1), and were tested 24 h later, 5 min after pre­
test intra-CA1 administration of phenylephrine (0.0, 0.125, 0.25, 
0.5 and 1 lg/rat) plus saline (1 ll/rat, intra-CA1). A further ﬁve groups of animals received scopolamine (2 lg/rat, intra-CA1) 
immediately after training. On the test day, the animals received 
the same doses of phenylephrine plus scopolamine (0.25 lg/rat, in­
tra-CA1) 5 min before testing (Fig. 3). 2.9.3. Experiment 3: effects of pre-test administration of prazosin on 
memory retrieval in the presence or absence of scopolamine 
On the training day, all animals received post-training adminis­
tration of saline (1 ll/rat, intra-CA1) or scopolamine (2 lg/rat, in­
tra-CA1). On the test day, the animals received pre-test intra-CA1 
administration of, prazosin (0.0, 0.5, 1 and 2 lg/rat, intra-CA1) plus 
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Fig. 2. The effects of scopolamine on memory retrieval. Four groups of animals 
received post-training saline (1 ll/rat), or different doses of scopolamine (0.5, 1 and 
2 lg/rat, intra-CA1). On the test day, animals received saline (1 ll/rat, intra-CA1) 
5 min before the test. Other three groups of animals received post-training injection 
of saline (1 ll/rat) and pre-testing injections of different doses of scopolamine (0.5, 
1 and 2 lg/rat, intra-CA1). In another four groups, the animals received post-
training administration of a high dose of scopolamine (2 lg/rat, intra-CA1) and pre­
testing injections of different doses of scopolamine (0.25, 0.5, 1 and 2 lg/rat, 
intra-CA1). Data are expressed as mean ± SEM of eight animals per group. 
***P < 0.001different from post-training saline/pre-test saline group. +P < 0.05, 
+++P < 0.001different from post-training scopolamine (2 lg/rat)/pre-test saline group. 
0 
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Fig. 4. The effects of pre-test administration of prazosin with or without scop
amine on the step-through latencies. All animals received post-training admin
tration of saline (1 ll/rat, intra-CA1) or scopolamine (2 lg/rat, intra-CA1) a
pre-test administration of different doses of prazosin (0.0, 0.5, 1 and 2 lg/r
intra-CA1) before the administration of saline (1 ll/rat, intra-CA1) or scopolami
(2 lg/rat, intra-CA1). Data are expressed as mean ± SEM of eight animals per gro
**P < 0.01, ***P < 0.001different from scopolamine/scopolamine group. 
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combination with scopolamine (2 lg/rat; Fig. 4, right panel). The 
step-through latency was measured 5 min after the last injection.        
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Fig. 3. The effects of pre-test administration of phenylephrine with or without 
scopolamine on the step-through latencies. In one series, all animals received post-
training administration of saline (1 ll/rat, intra-CA1), and pre-testing, administra­
tion of phenylephrine (0.0, 0.125, 0.25, 0.5 and 1 lg/rat, intra-CA1) before saline 
(1 ll/rat, intra-CA1). In another groups, the animals received post-training admin­
istration of scopolamine (2 lg/rat, intra-CA1) and pre-test injection of phenyleph­
rine (0.0, 0.125, 0.25,0.5 and 1 lg/rat, intra-CA1) before the administration of saline 
(1 ll/rat, intra-CA1) or scopolamine (0.25 lg/rat, intra-CA1). Data are expressed as 
mean ± SEM. of eight animals per group. ***P < 0.001 different from saline/saline 
group. +++P < 0.001different from scopolamine/saline group. øøP < 0.01, .øøøP < 0.001 
different from scopolamine/scopolamine group.2.9.4. Experiment 4: effects of pre-test administration of clonidine 
memory retrieval in the presence or absence of scopolamine 
In this experiment, four groups of animals received saline (1 
rat, intra-CA1) immediately after training and different doses 
clonidine (0, 0.25, 0.5 and 1 lg/rat, intra-CA1) plus saline (1 
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Fig. 5. The effects of pre-test administration of clonidine with or without 
scopolamine on the step-through latencies. In one series, all animals received 
post-training administration of saline(1 ll/rat, intra-CA1), and pre-testing, admin­
istration of clonidine (0.0, 0.25, 0.5 and 1 lg/rat, intra-CA1) before saline (1 ll/rat, 
intra-CA1). In another groups, the animals received post-training administration of 
scopolamine (2 lg/rat, intra-CA1) and pre-test injection of clonidine (0, 0.25, 0.5 
and 1 lg/rat, intra-CA1) before the administration of saline(1 ll/rat, intra-CA1) or 
scopolamine (0.25 lg/rat, intra-CA1). Data are expressed as mean ± SEM. of eight 
animals per group. ***P < 0.001 different from post-training saline/pre-test saline 
group. +P < 0.05, +++P < 0.001different from post-training scopolamine /pre-test 
saline group. øP < 0.05, øøøP < 0.001 different from post-training scopolamine/pre­
test scopolamine group. 
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post-training administration of scopolamine (2 lg/rat, intra-CA1), 
and were tested 24 h later, 5 min after pre-test intra-CA1 adminis­
tration of clonidine (0, 0.25, 0.5 and 1 lg/rat) plus saline (1 ll/rat, 
intra-CA1) and. A further four groups of animals received scopol­
amine (2 lg/rat, intra-CA1) immediately after training. On the test 
day, the animals received the same doses of clonidine plus scopol­
amine (0.25 lg/rat, intra-CA1) 5 min before testing (Fig. 5) 
2.9.5. Experiment 5: effects of pre-test administration of yohimbine on 
memory retrieval in the presence or absence of scopolamine 
On the training day, all animals received post-training adminis­
tration of saline (1 ll/rat, intra-CA1) or scopolamine (2 lg/rat, in­
tra-CA1). On the test day, the animals received pre-test intra-CA1 
administration of yohimbine (0.0, 0.5, 1 and 2 lg/rat, intra-CA1) plus 
saline (Fig. 6, left panel) or yohimbine (0.0, 0.5, 1 and 2 lg/rat) in 
combination with scopolamine (2 lg/rat; Fig. 6, right panel). The 
step-through latency was measured 5 min after the last injection. 3. Results 
3.1. Histology 
Fig. 1 illustrates the approximate point of the drug injections in 
the CA1 from animals (B). The histological results were plotted on 
representative sections taken from the rat brain atlas of (Paxinos & 
Watson, 2007) (A). Only data from animals with correct cannulae 
implants (432 animals; 93.5% of the total) were included in the sta­
tistical analyses. 
3.2. Effects of Scopolamine on memory retrieval 
Fig. 2 shows the effects of post-training (left panel) or pre-test 
(middle panel) intra-CA1 administration of scopolamine on step-
through latency. One-way ANOVA revealed that post-training 
[F(3, 28) = 13.18, P < 0.001] or pre-test [F(3, 28) = 19.29, P < 0.001] 
scopolamine (0.5, 1 and 2 lg/rat, intra-CA1) dose-dependently re-  
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Fig. 6. The effects of pre-test administration of yohimbine with or without 
scopolamine on the step-through latencies. All animals received post-training 
administration of saline(1 ll/rat, intra-CA1) or scopolamine (2 lg/rat, intra-CA1) 
and pre-test administration of different doses of yohimbine (0.0, 0.5, 1 and 2 lg/rat, 
intra-CA1) before the administration of saline (1 ll/rat, intra-CA1) or scopolamine 
(2 lg/rat, intra-CA1). Data are expressed as mean ± SEM of eight animals per group. 
**P < 0.01, ***P < 0.001 different from scopolamine/scopolamine group. duced the step-through latency in the inhibitory avoidance task, 
showing scopolamine-induced amnesia. Furthermore, there was 
no signiﬁcant difference between the number of trials to acquisition 
in animals that received scopolamine after training [F(3, 28) = 1.15, 
P > 0.05] or before testing [F(4, 35) = 1.28, P > 0.05] by itself and thus 
conﬁrmed their uniformity (data not shown). 
Fig. 2 (right panel) indicates that animals in which retrieval was 
impaired due to post-training administration of scopolamine (sco­
polamine-induced amnesia), pre-test scopolamine (0.5, 1 and 
2 mg/kg) restored the retrieval to the control level (scopolamine 
state of memory) [one-way ANOVA, F(4, 35) = 16.42, P < 0.001]. In 
addition, the number of trials to acquisition among the groups of 
rats used in this experiment was not signiﬁcant [F(3, 28) = 1.62, 
P > 0.05] and thus conﬁrmed their uniformity (data not shown). 3.3. Effects of pre-test administration of phenylephrine on memory 
retrieval in the presence or absence of Scopolamine 
Fig. 3 indicates the effects of pre-test intra-CA1 injection of phen­
ylephrine in the presence or absence of scopolamine on memory re­
trieval. Two-way ANOVA indicated an interaction between the 
groups of animals which received post-training saline (1 ll/rat) 
and pre-test phenylephrine (0,0.125, 0.25, 0.5 and 1 lg/rat, intra­
CA1) and those which received post-training scopolamine (2 lg/ 
rat, intra-CA1) and pre-test phenylephrine [for Treatment, 
F(1, 70) = 34.8, P < 0.001; Dose, F(4, 70) = 6.2, P < 0.001; and Treat­
ment x Dose interaction, F(4, 70) = 2.5, P < 0.05] on memory retrie­
val. Two-way ANOVA also revealed a signiﬁcant difference 
between the groups of animals which received post-training saline 
(1 ll/rat) and pre-test phenylephrine and those which received 
post-training scopolamine (2 lg/rat, intra-CA1), followed by pre­
test phenylephrine plus a lower dose of scopolamine (0.25 lg/rat, in­
tra-CA1) [for Treatment, F(1, 70) = 7.1, P < 0.01; Dose, F(4, 70) = 7.41, 
P < 0.001; and Treatment x Dose interaction, F(3, 70) = 2.96, 
P < 0.001] on memory retrieval. Furthermore, two-way ANOVA re­
vealed a signiﬁcant difference between the groups of animals which 
received post-training scopolamine (2 lg/rat, intra-CA1) and pre­
test phenylephrine and those which received post-training scopol­
amine (2 lg/rat, intra-CA1), followed by pre-test phenylephrine plus 
a lower dose of scopolamine (0.25 lg/rat, intra-CA1) [for Treatment, 
F(1, 70) = 14.68, P < 0.001; Dose, F(4, 70) = 17.79, P < 0.001; and 
Treatment x Dose interaction, F(4, 70) = 3.33, P < 0.05] on memory 
retrieval. In addition, post-hoc analysis revealed that in the animals 
that received saline after training and tested following intra-CA1 
administration of phenylephrine (Fig. 3, left panel), no signiﬁcant 
change was observed in the retrieval latencies [F(4, 35) = 1.74, 
P > 0.05] and the number of trials to acquisition [F(4, 35) = 1.22, 
P > 0.05; data not shown] as compared with the saline/saline control 
group. Furthermore, in the animals that post-training administra­
tion of scopolamine (2 lg/rat, intra-CA1) impaired memory retrie­
val, administration of phenylephrine (1 lg/rat), on the test day, 
signiﬁcantly [F(4, 35) = 9.56, P < 0.001] reversed retrieval impair­
ment (Fig. 3, middle panel). Moreover, the lower dose of pre-test sco­
polamine (0.25 lg/rat, intra-CA1) alone did not induce a signiﬁcant 
scopolamine state-dependent memory. However, co-administra­
tion of the higher doses of phenylephrine (0.25,0.5 and 1 lg/rat, in­
tra-CA1) with 0.25 lg/rat of scopolamine signiﬁcantly improved the 
memory retrieval and mimicked the effects of pre-test administra­
tion of a higher dose of scopolamine treatment [F(4, 35) = 11.472, 
P < 0.0001] (Fig. 3, right panel). In addition, there was no signiﬁcant 
difference between the number of trials to acquisition in animals 
that received scopolamine after training and tested following in­
tra-CA1 administration of phenylephrine by itself [F(4, 35) = 1.14, 
P > 0.05] or phenylephrine plus scopolamine [F(4, 35) = 1.68, 
P > 0.05] and thus conﬁrmed their uniformity (data not shown). 
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in the presence or absence of Scopolamine 
Fig. 4 shows the effect of pre-test intra-CA1 administration of pra­
zosin in the presence or absence of scopolamine on memory retrie­
val. Two-way ANOVA indicated a signiﬁcant difference between 
the effects of prazosin (0.0, 0.5, 1 and 2 lg/rat, intra-CA1) alone 
and prazosin plus scopolamine (2 lg/rat, intra-CA1) on memory re­
trieval [for Treatment, F(1, 56) = 15.56, P < 0.001; Dose, F(3, 56) = 
5.09, P < 0.01; and Treatment x Dose interaction, F(3, 56) = 4.15, 
P < 0.01]. One-way ANOVA also revealed that in the animals trained 
before saline treatment and tested following intra-CA1 administra­
tion of three different doses of prazosin (0.5, 1 and 2 lg/rat, intra­
CA1), no signiﬁcant change was observed in the retrieval latencies 
[F(3, 28) = 0.6, P > 0.05] and the number of trials to acquisition 
[F(3, 28) = 0.74, P > 0.05; data not shown] as compared with saline/ 
saline control group. Furthermore, in the animals which received 
post-training and pre-test administration of scopolamine (2 lg/rat, 
intra-CA1), pre-test intra-CA1 administration of prazosin decreased 
the improvement of memory retrieval by pre-test scopolamine 
(2 lg/rat, intra-CA1) treatment [F(3, 28) = 12.2, P < 0.0001], while, 
there was no signiﬁcant difference between the number of trials to 
acquisition [F(3, 28) = 1.52, P > 0.05; data not shown]. 
3.5. Effects of pre-test administration of clonidine on memory retrieval 
in the presence or absence of Scopolamine 
Fig. 5 indicates the effects of pre-test intra-CA1 injection of clo­
nidine in the presence or absence of scopolamine on memory re­
trieval. Two-way ANOVA indicated an interaction between the 
groups of animals which received post-training saline (1 ll/rat) 
and pre-test clonidine (0, 0.25, 0.5 and 1 lg/rat, intra-CA1) and 
those which received post-training scopolamine (2 lg/rat, intra­
CA1) and pre-test clonidine [for Treatment, F(1, 56) = 23.02, 
P < 0.001; Dose, F(3, 56) = 4.46, P < 0.01; and Treatment x Dose 
interaction, F(3, 56) = 5.41, P < 0.01] on memory retrieval. Two-
way ANOVA also revealed a signiﬁcant difference between the 
groups of animals which received post-training saline (1 ll/rat) 
and pre-test clonidine and those which received post-training sco­
polamine (2 lg/rat, intra-CA1), followed by pre-test clonidine plus 
a lower dose of scopolamine (0.25 lg/rat, intra-CA1) [for Treat­
ment, F(1, 56) = 9.57, P < 0.01; Dose, F(3, 56) = 4.1, P < 0.05; and 
Treatment x Dose interaction, F(3, 56) = 5.57, P < 0.01] on memory 
retrieval. Furthermore, two-way ANOVA revealed a signiﬁcant dif­
ference between the groups of animals which received post-train­
ing scopolamine (2 lg/rat, intra-CA1) and pre-test clonidine and 
those which received post-training scopolamine (2 lg/rat, intra­
CA1), followed by pre-test clonidine plus a lower dose of scopol­
amine (0.25 lg/rat, intra-CA1) [for Treatment, F(1, 56) = 3.51, 
P > 0.05; Dose, F(3, 56) = 25.03, P < 0.001; and Treatment x Dose 
interaction, F(3, 56) = 0.33, P > 0.05] on memory retrieval. In addi­
tion, post-hoc analysis revealed that in the animals that received 
saline after training and tested following intra-CA1 administration 
of clonidine (Fig. 5, left panel), no signiﬁcant change was observed 
in the retrieval latencies [F(3, 28) = 0.16, P > 0.05] and the number 
of trials to acquisition [F(3, 28) = 1.14, P > 0.05; data not shown] as 
compared with the saline/saline control group. Furthermore, in the 
animals that post-training administration of scopolamine (2 lg/ 
rat, intra-CA1) impaired memory retrieval, administration of cloni­
dine (1 lg/rat), on the test day, signiﬁcantly [F(3, 28) = 13.24, 
P < 0.001] reversed retrieval impairment (Fig. 5, middle panel). 
Moreover, the lower dose of pre-test scopolamine (0.25 lg/rat, in­
tra-CA1) alone did not induce a signiﬁcant scopolamine state-
dependent memory. However, co-administration of the higher 
doses of clonidine (0.25,0.5 and 1 lg/rat, intra-CA1) with 0.25 lg/ 
rat of scopolamine signiﬁcantly improved the memory retrieval and mimicked the effects of pre-test administration of a higher 
dose of scopolamine treatment [F(4, 35) = 12.42, P < 0.0001] 
(Fig. 5, right panel). In addition, there was no signiﬁcant difference 
between the number of trials to acquisition in animals that re­
ceived scopolamine after training and tested following intra-CA1 
administration of clonidine by itself [F(4, 35) = 1.06, P > 0.05] or 
clonidine plus scopolamine [F(4, 35) = 1.29, P > 0.05] and thus con­
ﬁrmed their uniformity (data not shown). 3.6. Effects of pre-test administration of yohimbine on memory 
retrieval in the presence or absence of Scopolamine 
Fig. 6 shows the effect of pre-test intra-CA1 administration of 
yohimbine in the presence or absence of scopolamine on memory 
retrieval. Two-way ANOVA indicated a signiﬁcant difference be­
tween the effects of yohimbine (0, 0.5, 1 and 2 lg/rat, intra-CA1) 
alone and yohimbine plus scopolamine (2 lg/rat, intra-CA1) on 
memory retrieval [for Treatment, F(1, 56) = 13.74, P < 0.001; Dose, 
F(3, 56) = 6.13, P < 0.001; and Treatment x Dose interaction, 
F(3, 56) = 5.28, P < 0.01]. One-way ANOVA also revealed that in 
the animals trained before saline treatment and tested following 
intra-CA1 administration of three different doses of yohimbine 
(0.5, 1 and 2 lg/rat, intra-CA1), no signiﬁcant change was observed 
in the retrieval latencies [F(3, 28) = 0.8, P > 0.05] and the number of 
trials to acquisition [F(3, 28) = 0.93, P > 0.05; data not shown] as 
compared with saline/saline control group. Furthermore, in the 
animals which received post-training and pre-test administration 
of scopolamine (2 lg/rat, intra-CA1), pre-test intra-CA1 adminis­
tration of yohimbine decreased the improvement of memory re­
trieval by pre-test scopolamine (2 lg/rat, intra-CA1) treatment 
[F(3, 28) = 13.95, P < 0.0001], while, there was no signiﬁcant differ­
ence between the number of trials to acquisition [F(3, 28) = 0.95, 
P > 0.05; data not shown]. 4. Discussion 
Step-through is a model of inhibitory avoidance task which is 
widely used in pharmacological studies of long-term memory in 
rodents (Izquierdo & McGaugh, 2000; Izquierdo et al., 2006). The 
present data indicated that post-training or pre-test intra-CA1 
administration of scopolamine by itself impaired memory retrieval 
on the test day. In agreement with our present studies, several 
lines of evidence have been reported that acetylcholine is a crucial 
mediator of learning and memory (Blokland, 1995). There are dif­
ferent reports indicating that scopolamine impairs learning in dif­
ferent tasks, which is directly related to a decrease in central 
cholinergic functions (Fibiger, 1991; Gallagher & Colombo, 1995). 
In many behavioral paradigms, the deﬁcits produced by muscarinic 
cholinergic antagonism are similar to the effects produced by hip­
pocampal lesions (Watts, Stevens, & Robinson, 1981). The degener­
ation and dysfunction of cholinergic neurons is also closely 
associated with the cognitive deﬁcits of Alzheimer’s disease (Bar­
tus, Dean, Beer, & Lippa, 1982; Coyle, Price, & DeLong, 1983). Fur­
thermore, the present data showed that amnesia induced by post-
training scopolamine (2 lg/rat, intra-CA1) was completely re­
stored by injecting the same dose of scopolamine before testing, 
a similar response has been shown for morphine (Khavandgar, 
Homayoun, Torkaman-Boutorabi, & Zarrindast, 2002; Zarrindast 
et al., 2006), lithium (Zarrindast, Madadi, & Ahmadi, 2008; Zarrind­
ast et al., 2005a) and histamine (Zarrindast, Fazli-Tabaei, Khalil­
zadeh, Farahmanfar, & Yahyavi, 2005b; Zarrindast, Khalilzadeh, 
Malekmohammadi, & Fazli-Tabaei, 2006), which has been consid­
ered as state-dependent memory. 
Previous studies of post-training administration of adrenergic 
agonists such as epinephrine (Introini-Collison, Castellano, & 
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ephrine (Ferry, Roozendaal, & McGaugh, 1999a, 1999b) demon­
strated memory enhancing effects, primarily in memory-deﬁcit 
models. The results obtained in this investigation revealed that 
pre-test intra-CA1 microinjection of the different doses of a1-nor­
adrenergic agonists, phenylephrine or a2-noradrenergic agonists, 
clonidine reversed the memory impairment induced by post-train­
ing administration of scopolamine. Furthermore, pre-test co-
administration of non-effective doses of the phenylephrine or clo­
nidine with a dose of scopolamine (0.25 lg/rat), which by itself did 
not induce a response, restored memory impairment due to post-
training scopolamine injection. Thus, a1- and a2-noradrenergic 
receptor mechanisms of the CA1 region of dorsal hippocampus 
may be involved in this response. a2-adrenoceptors can be located 
both post- and pre-synaptically on forebrain and hippocampal 
neurons, and as autoreceptors in the locus coeruleus (see introduc­
tion). Therefore, the effect of clonidine may be mediated either 
through pre- or post-synaptic a2-adrenoceptor site. Stimulation 
of pre-synaptic a2-adrenoceptors receptors, located on adrenergic 
and non-adrenergic cells decreases the release of norepinephrine, 
acetylcholine and glutamate in target areas (Dennis, L’Heureux, 
Carter, & Scatton, 1987; Kamisaki, Hamahashi, Hamada, Maeda, & 
Itoh, 1992; Pudovkina & Westerink, 2005; Tellez, Colpaert, & Mari-
en, 1997; Tellez, Colpaert, & Marien, 1999). However, the post-syn­
aptic a2-adrenoceptors activation mimics the effect of 
norepinephrine (Arnsten & Leslie, 1991). 
The data may be supported by previous investigations showing 
that clonidine effectively ameliorated the memory deﬁcits pro­
duced by phencyclidine or MK-801 (blocker of NMDA receptors). 
The effects of these antagonists on memory have been suggested 
to be mediated through hippocampus, since microinfusions of 
NMDA antagonists into the hippocampus disrupt memory (Aura 
& Riekkinen, 1999; Yoshihara & Ichitani, 2004). The ascending nor­
adrenergic ﬁber that originate from locus coeruleus and innervate 
various brain areal, has been shown to participate in behavioral 
ﬂexibility, attention, and the facilitation of processing of novel or 
signiﬁcant sensory stimuli (Aston-Jones, Rajkowski, & Cohen, 
2000; Berridge & Waterhouse, 2003; Bouret & Sara, 2004). Further­
more, the a1-adrenoceptor agonist, phenylephrine may increase 
the memory retrieval via post-synaptic a1-adrenoceptors (Coull, 
1994). Activation of these post-synaptic a1-adrenoceptors potenti­
ates b-adrenoceptor mediated activation of cAMP formation (Ferry 
et al., 1999a). Moreover, a1-adrenoceptors are implicated in medi­
ation of the effects of norepinephrine on storage and their action 
depends on concurrent b-adrenoceptor activation (Ferry, Roo­
zendaal, & McGaugh, 1999b). 
In addition, the present study investigated the effects of pre-test 
microinjection of a1-adrenergic receptor antagonist, prazosin or 
a2-adrenergic receptor antagonist, yohimbine with or without sco­
polamine on memory retrieval. In the animals which received post-
training and pre-test administration of scopolamine (2 lg/rat, in­
tra-CA1), pre-test intra-CA1 administration of prazosin or yohim­
bine decreased the improvement of memory retrieval by pre-test 
scopolamine (2 lg/rat) treatment. Indeed, prazosin and yohimbine 
signiﬁcantly inhibited scopolamine-state-dependent memory, 
which may indicate that the scopolamine response is mediated 
through the CA1 a-adrenergic receptor system. The decrease in re­
trieval now induced by prazosin may agree with ﬁndings of others 
indicating that prazosin decreases acquisition of memory (Obersz­
tyn & Kostowski, 1983; Riekkinen, Stefanski, Kuitunen, & Riekki­
nen, 1996). Other investigators showed that pre- or post-training 
infusion of prazosin into the bed nucleus of the stria terminalis 
(BNST) impaired acquisition or retrieval of a spatial navigation re­
sponse in Morris water maze, whereas infusion of norepinephrine 
into the same region improved acquisition or retrieval, and this 
enhancement was attenuated by simultaneous infusion of prazosin (Chen, Chen, Chen, & Liang, 2004). Furthermore, our results indi­
cate that in the animals trained before saline treatment and tested 
following intra-CA1 administration of prazosin or yohimbine, in 
the doses used, did not affect memory retrieval. Previous studies 
demonstrated that post-training intracerebroventricular injection 
of prazosin but not yohimbine reduced memory retrieval in rats 
(Zarrindast, Khodjastehfar, Oryan, & Torkaman-Boutorabi, 2001). 
Furthermore, peripheral pre-test intraperitoneal administration 
of prazosin but not yohimbine decreased the retrieval latency (Zar­
rindast, Bakhshaet, et al., 2002, Zarrindast, Eidi, et al., 2002). Other 
studies indicate yohimbine, could impair the spatial working 
memory in monkeys, and the memory deﬁcits could be reversed 
by a2-adrenoceptor agonists (Arnsten, Cai, & Goldman-Rakic, 
1988; Arnsten & Goldman-Rakic, 1985; Cai, Ma, Xu, & Hu, 1993), 
but pre-test intra-CA1 administration of the doses of prazosin or 
yohimbine used in the present study was selected on the basis of 
a pilot study which showed that these drug did not have any effect 
by themselves on the step-through latencies of inhibitory avoid­
ance task. 
In conclusion, considering that post-training scopolamine-in­
duced amnesia can be decreased by pre-test injection of a1- and 
a2-adrenergic agonists and inhibition of memory retrieval in the 
animals which received both post-training and pre-test adminis­
tration of scopolamine by the adrenergic antagonists, it is possible 
that scopolamine state-dependent memory may be related to acti­
vation of the CA1 adrenergic system. However, more experiments 
are required to clarify the exact mechanism(s) involved in the 
interaction between scopolamine and a-adrenoceptors. Appendix A. Supplementary material 
Supplementary data associated with this article can be found, in 
the online version, at doi:10.1016/j.nlm.2010.01.003. References 
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